RVNC - Earnings call transcript Q4 2021 | Revance Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

0:04 Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.

Following management’s prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions during the Q&A session, we will ask for a limit of one question and one follow up question per person. [Operator Instructions]. this being reminder, February today, a XXXX. XXth, As call recorded is Monday X:XX like the ESG to to now would I turn Head Investor Jessica conference of Relations Revance. and for Serra, over call ahead. Please go

Jessica Serra

you, Thank Victor. X:XX

Joining Officer, Foley; Officer, Executive Toby us are Chief Sjuts; Mark today from President, the Revance, on Chief and Schilke. Dustin Financial call

DaxibotulinumtoxinA glabellar this call, management and statements as regulatory the to potentional in conference plans will approval including therapeutic in platform. During related collection process of timing for well as of to approval related lines and make forward-looking Injection and indications, statements, OPUL RHA

our Our priorities, and business our rate, planned and company's financial XXXX are services and These operations run plans, strategy, and strategic the and and on allocation statements for current runway, uncertainties. market involve our looking cash the expectations products performance capital inherently and volume based risks revenue forward and guidance, plans. processing X:XX commercialization opportunity expected demand significant market

our non-GAAP that over and reconciliation financial A Revance. included X:XX of Foley timing risks Our huge those both statements Mark. of actual Chief GAAP result Mark will I to release. of results and measures. call, is measures in will non-GAAP turn on call as a earnings we forward With of events in to today’s such anticipated the present differ uncertainties. looking Also from and Executive GAAP materially could the Officer

Mark Foley

year and and people now take to platform, Strong our our $XX afternoon, the be everyone. Revance’s scale With our and year over latest pleased marked share Jessica. We X:XX of recent led years our were to treatment collection, we the which US action capital RHA to lines, we XXXX. across as over over you that $X.X continues key billion and the allocation, provides X:XX full US commercial date inclusion. call. year dermal innovation into the services. ahead. XXXX continue dermal million to acid products X results ending franchise, filler injection X,XXX to fintech ability FDA be and our I’d fourth execution, more for full deferred Good These we Coming in our Thank priorities payment gross filler like updates. conference Our across filler the priorities. X:XX culture focus in and commercial to of cannot first in the year. with our glabellar in well joining for large as and therapeutics core results with you, November customers technology market. strategic that our PDUFA advancement for Thank for have these our and review financial some growing have disciplined accounts quarter advancement in in approval of and volume diversity for on Obtaining following on the of DaxibotulinumtoxinA will gain track the how hyaluronic focus execution, generated by XXXX, moment a XXXX a

bank. drug we possible. DaxibotulinumtoxinA paves as for for First, announced BLA we approval Earlier required the resubmission not the we've made our manufacturing The soon had in qualification did new manufactured products lot that progress for while successfully completion neuromodulator we path. the today, our one we as X of meaningful regulatory injection product for for slots, way advancing the receive our FDA activities of FDA consecutive and drug anticipated, as by cell glabellar as the for working lines or substance

cell substance cell complete bank, manufacturing address of the process a related new the in us our to, our our December, working very manner. underway we on we Qualification the qualification already based activities outstanding in A You'll the X and qualify a process X X drug our completed have announced product with Type time new timely lot. lots pleased producing to agency qualification recall required consecutive was and working substance meeting meeting observations response to at were results, drug the drug and our bank by to Type that X, A

Phase which adult with the X demonstrating therapeutic drug to spasticity program indication, X program, DaxibotulinumtoxinA turn the the requirements a extended facility, well-tolerated completed complete successfully execution to months cervical as necessary agency X In is in on the BLA. resubmitted this indications. XXXX, resubmission this Phase to package based on opening now re-inspection injection, meeting productive will As Further our program X Phase working soon our informed second generally and advancement product our based as our clinical For accepted, accepted across we focused for our now possible and completed aesthetic our my for the on with clinical we've approved we remain already I on are the meeting, dressed to therapeutics by is our We Type of review resubmission will the the franchise. our also safe for to Phase update and spasticity. regulations, The forward and the its marked was completion program and of X:XX a for previously, profile neuromodulator have with both of upper and and of cervical an our adult an agency manufacturing dystonia will getting dystonia provide the facilitate for facility we X successfully held indication. our commercial and As the limb BLA. A program resubmitted duration once limb resubmission X:XX strategic X be re-inspection a up for along agency. with third our the engaging look program FDA, has clinical both FDA once upper I once Phase our indicated X:XX process. We completed XXXX, of that our priority clinical for remarks, ASPEN Phase X our

we glabellar Given poised file our the for and BLA to cervical a following supplemental dystonia lines. are injection approval DaxibotulinumtoxinA progress, in

conservation program, delayed limb some of we given of spasticity year upper late For last measures to implemented approval the cash adult our the neuromodulator. due that

the and We have in X its proper timing and To X:XX that prudent to been and we pursuing X:XX allowed in of Finally, continue efforts the the into policies challenges the us to year, due spite of to CRL end that following maximize efforts evaluating to have throughout flexibility. we financial hybrid that generate balance evaluate for by our in our commencement to remote capital presented will initiation. growth Phase and end, ongoing pandemic. have disciplined the particularly for Turning costs have program to cash XXXX. the will return paused we been stockholders. opportunities the These with our our highest COVID-XX allocation, our work year

strategic fourth Before year the strong and Of hard over and priorities to talent Dustin educational engagement would like review We embraces for inclusion our while turn through also X:XX across to involve creating These to us I diversity spanning corporate walk note, goals to acquisition, all met culture diversity that operational for our we across foster XXXX. I employee achievements, programs priorities the inclusion. initiatives of quarter successfully organization. a and internal and have worked leadership call the and levels forums.

a as approval DaxibotulinumtoxinA as goal. soon bring us which on closer gaining step FDA for to that First, lines our in actively glabellar primary for injection working possible. We're will resubmission, one remains goal

fillers of Our top the dermal second be to drive to RHA which by collection is and priority to services, for products continue in anchored growth line continue will XXXX.

is have fourth Third, allocation Fifth on we which built. deeper in of to in drive and and relational and drive the capital With value XXXX, people the expand that the our able we for finally, migration Revance the I'm to success focus plan and continue let forward Dustin? of X:XX long-term shared we platform's will look all call for OPUL our platform, to are Dustin our will completed dedication in invest the to that, culture now continue me efforts penetration to our who our we functionality. to in to will performance quarter. XXXX. discipline cover thankful turn upon and stockholders. Fourth, organization PayFac success over the I our commerce

Dustin Sjuts

X:XX Mark. Thank you,

your and supported strong start the hard across in fourth increase everyone by In representing which a first pulled $XX.X we've all of we launch seasonality. capped strategy, differentiate advanced of Revance growth, XXXX, execution the our Let by our RHA during million work traditional year RHA In year technology commercialization over made account the account by competitors. appreciation These to the and other across the off and an RHA full aesthetic our increased productivity million in sale. quarter, $XX.X X:XX sale therapeutics. and from new driven continue organization for are results impact first over quarter, of progress echoing me XXX% aesthetics recording total are innovative both to

and second We're collection. and quarters we Redensity as and fourth to cross for on opportunities year. strongest as to are typically we introduce in our periods XX:XX static XXXX, our excited particularly the calendar momentum procedures products RHA leverage each in to The build RHA selling services

of of FDA X the to further rhytids referred The lip of treatment end options. approved The half of the lines adaptable. in RHA was SA, RHA by moderate-to-severe in You'll RHA as for dynamic, perioral clinical versatility launching we second year. the approval recall Redensity, natural our collection, XX:XX dynamic received well partner the range Teoxane injectors providing investigators treatment previously at now which The and includes indication XXXX, Redensity look was product the RHA X. with that wider trials, the or for augments to forward a are received and collection formulations distinct of

the It's help of both a include platform, bring launch analytics, Turning important payments, fulfill X,XXX the enable was catalogue SKUs. OPUL. currently needs to to the our first commerce and and launch the will of operations optimize platform innovation relationships. unmet Initial an its continue aesthetic industry. Aesthetics highlight options new injectors of to Teoxane market consumer FinTech filler while practice the with are XXXX relational working of to of kind We that us consumers. designed over checkout to customizable practices to reporting, features for seamless and OPUL enhancing containing XX:XX

and will account with consumers. new practices that almost is to we're end. nearly rate run over team retention. penetration, practice The features and run develop meaningful $XXX rate to are increased to processing and developing began adoption We enhance million that at a leveraging XX:XX currently to XXXX million to able membership We payment year through both triple programs be insights $XXX

payment our As FinTech volume processing platform. is performance a previously key indicated indicator we for

year as the XXXX, period in or Toby turn processed OPUL XXXX, With all and our call grow net and Going our goal our is to to to providing the we'll HintMD our financials. new that, transactions accounts, total dollar our In $XXX payment full of legacy was to be the For forward, to migration platform's, year over HintMD volume, I'll million. to GPV develop GPV, gross refunds. amount of continue the OPUL. XX:XX features our our the of full defined cover fourth and quarter complete customers

Toby Schilke

Thank from in quarter was $XX.X and full Dustin, fintech annual million of the $X.X XXXX. quarter financial report revenue and the from of and partnership to dermal $XX.X growth Revenue for our sales collection RHA for for $XX.X to RHA of service are collaboration the increased for and basis $X.X million by a primarily dermal revenue pleased XX:XX of revenue included fourth on same of the year. year strong and driven $XX.X for period fillers. XXXX million million collection our fourth fourth and platform. we product Revenue $XX.X million, you Revenue compared of million results from Viatris with quarterly fillers, million the the quarter the was

million For our revenue million million product included platform. XXXX $X.X collaboration the $X.X revenues FinTech from our of $XX.X year, revenue, of and

were XXXX of full for the and year our year of revenues $X.X million and our expenses quarter $XX.X stock-based $X.X the for compensation. excluding million $XX.X and $XXX.X For operating the were and collaboration expenses year, platform. product and quarter $XX.X XX:XX million fourth $XXX.X fourth from Operating Non-GAAP and million revenue, million included million revenue, full depreciation for FinTech the million year. XXXX the for amortization

for allocation We products relationships services, customer with line taken capital focused is and and GAAP by well Phase our our our FDA obtaining program deepening for conserve our a to XX:XX in commercial and also folks top the pipeline and expenses Due announced and non-GAAP limb mentioned, X DaxibotulinumtoxinA operating time exception DaxibotulinumtoxinA and regulatory ranges. investing guidance for other preserve pausing prudent these of collaboration activities to our investments below OPUL driving in previously on this China. therapeutic and cash non-critical upper XX:XX approval on injection, efforts, people our or specificity, culture. and our hires for through for with injection, clinical growth pausing deferring As expanding steps previously the for as year international as with at have

cost approved. expect shares equivalents million, is non-GAAP R&D costs according Looking for XX:XX $XXX our as of February to to are costs period over XXXX, were December driven diluted million to standards is believe compensation outstanding Revance’s with expenses ahead, expense we primarily by I'll of Finally, investments with operating stock and amortization turn to shares, to which fully revenue, $XX.X and Further, our common back XX, XX:XX million be operating $XXX to our of XXXX. and we short-term expect and expenses $XXX And that, fund to planned excluding GAAP XXXX call convertible of the research are operations product are manufacturing accounting $XXX Mark. stock-based development drug cash, of for debt. the GAAP XX:XX million the and impact in $XXX Turning to expensed million million million as balance XXXX to injection, expenses, be $XXX.X a which XXXX, to we $XX.X exclude sufficient cash into DaxibotulinumtoxinA approximately non-GAAP million. $XXX sheet, million. be as XX, depreciation until which

Mark Foley

that have with is aesthetic you, elite commercial for our us forge will the desired Toby. practices strategy a commercial into we provide closing, Thank approved. strong us while In to results, delivering differentiated allowing also inroads XX:XX that neuromodulator foundation once a

our With all also XXXX support DaxibotulinumtoxinA obtaining will for cervical for look only us on stockholders for by priority in call our forward Operator? will is XX:XX up approval dystonia. for for way line, the I'd supplemental in continued to accelerate of pave I new for filing aesthetics, injection that, your you but to the I thank open in Revance. updating main the opportunity not like for questions. BLA therapeutics growth advance FDA our which progress glabellar to our year. for now a Our should

Operator

[Operator XX:XX Ken Cacciatore Cowen. question Our Instructions] from first

You may begin.

Ken Cacciatore

context us the waiting would is it the you the is much. on Thanks (ph)? a XX:XX Thanks great progress, be then timing hear around much. Is little just you you Can cell all anything it? working characterize weeks there guys. that? the qualification of Great can so bit the here refiling. filing and to else it the XXX Can from Or bank of just of – for Mark, we so the wondering or help on put months?

Mark Foley

XX:XX Yeah, I can.

we're to But So for timing, lead give long it. going bank. the on -- the one, the we're first item not cell work the clearly, related new working was to qualification specifics the

will public BLA. definitely announcement once little a we indicated, have and it's the together we point, pull out more nature put refiled this at we bit to everything administrative in as just So a

drug high this to point. out said regards nature the and again, one bank, what items XX:XX for previously, consecutive level was And of went were administrative items through in the then the drugs of see FDA working responses responses that is Type to three and the XXX we path. efficient into A the coming In qualification at of with and X for and Type focus product the indicated for – meeting appears our new A substance meeting a X this So the in it's that cell there wanted us. agency the to obviously, X more our X, agency XXX,

and complete in need we've will much on sort actual we've in that activities just the another what just we on response, portion the a that's on providing, aware the update been working of to relates we're applications from been name that's to of pretty but those it that, parallel. our as clinical it of search safety and So, name, working perspective and

Ken Cacciatore

XX:XX Great. so much. Thanks

Mark Foley

Thanks. XX:XX

Operator

line may begin. next Guggenheim, question from in Fernandez comes Our Seamus you XX:XX

Unidentified Analyst

the for XX:XX turnaround Hey, taking Seamus, question Alena there, congrats quick with this is and on your [Indiscernible]. on for thanks

a royalty DAXI? peak the in potential considering raise just you. question ’XX color we any that beyond particular, capital, company interest So have in transaction but would that validate that and potential of Any you're financing a only on sales not for would range options any Thank regarding, be the great. would on be

Toby Schilke

XX:XX Thanks Toby is a lot. This Schilke.

You operations our know, cash XXXX. as the on sufficient fund we call, to we have noted into

we priority that profile priority. take a are Daxi, of needs, we cash to a revenue we strategies variety specifics, a comment our so stage extending our as key while thoughtful cash cannot the we we a late have and we'll financing is balance top our approach optionality. runway with where and, Given are taking for this are Obviously, on

Unidentified Analyst

thank much. you XX:XX Awesome, very

Toby Schilke

XX:XX Welcome.

Operator

may will Our from Amsellem come from XX:XX next question you begin. David Piper sander,

David Amsellem

XX:XX Hey, thanks.

with So via just approval. RHA the a couple on

higher? XX%. something I I think you Europe, first or in the think secondly, you've broader Do question here. the an that's about the in X, that could RHA growing. products be think talk Thanks. market bump talk year know good you the about about a general? incremental the extent trajectory X% that, in which your that's peak general? the States? provide And you the where just How United could and opportunity that sales shares share you about can in Do Obviously, just do it like in then to had SKU, or could think you be said

Mark Foley

crack and David. I'll back it. part I'll that, of part think little the have first XX:XX Okay. maybe bit Thanks, that of Dustin a answer

Dustin Sjuts

Sure. XX:XX

David. So yeah, thanks,

– which for X dynamic agree or was perioral So called the anatomy. challenging the is only you a bit rhytids we're RHA Redensity, really to the of of lines, perioral as of treat region excited RHA because filler approval lip structure the did about facial formerly you approved which mention the

yet So we RHA toolbox us the of be for a that injectors. RHA natural unique RHA RHA Redensity most and the continues another that give X, tool RHA our a technology and RHA add allows RHA between and to in Redensity. feel us will mimic off that opportunity built X, is X

So continue us innovation addition of a about to at allows kind nice being to we this profile. and talk look

people the a kind is imagine, to superficial cake As a it is highlight you the allows of to filler, like utilization for, nice relates thing small in first volume, most on areas more we as a feel that it's of icing declines high kind that volume to of and continue the nor come portfolio. us

thin filler space, innovation So that So highlight new constantly to continue keep pass injectors, without with the to see we're this the that training over XX:XX over being you stream constant talking to relevant Mark. allow it us use of technology. more, to

Mark Foley

on just we and that markets the sort XX:XX we've on in your of what Yes, comments at market the of kind David, high thing, day And roughly about in billion market, trending said US EU Teoxane, the data $X.X the market right towards so little had had we're XX% top market grow. The continues now. of the last bit share, their what X to you're for depends now penetration our looking was right single-digit share share. that previously a

limited all do to are their where and or from the certainly been penetration standpoint there, think bundling that there we've going we've US we by once market. injector. effectively the don't the needs us in to are [Indiscernible] in we constraints So neuromodulators in allow certainly in feel there's going that more that terms to top partly a our fewer of it's meeting compete proved be because that of competitors in opportunity encouraged And to seen what

where that it's start, So or we us and to a going drive discounts. we neuromodulator from that to approved, we do is are opportunity believe with once to deeper give additional continue are certainly pleased

David Amsellem

Okay. Thank you. XX:XX Helpful.

Mark Foley

XX:XX Thank you David.

Operator

Annabel XX:XX line Our Samimy next of Stifel. question comes from

begin. may You

Annabel Samimy

the ask Thanks. the everything Revance suppose talked about on up goes platform, end according and an platform just you're progress. maybe then of quite question. launch then closely you've the get adding for And Are us working XX:XX on before on and start be of building a you whether then these what the practices you taking therapeutics not indications, Hi, and the the still effort past, commenting thanks hoping making OPUL given timing be FinTech in on resubmission? premature end my have Congratulations on resubmission. front year. further in the by I and any But with secondly, following to planning of that any regulatory to with the activities approval Aesthetics to aesthetics thoughts if should year the umbrella? of the plan the under when precluded you but and therapeutics same the

Mark Foley

Annabel, questions, let work so them. Good me and through try XX:XX

what said we into expect our in launch, timing, launch as with and the X-month and, XXXX sort and to the very are get we initiatives that priority months hopeful with the we've we're a any required these where would bank, to ready in therapeutics, of possible all the injectable we No, our talked therapeutic, stands therapeutic there of long thing facial of start we've that all. that, therapeutics agency's that, be build DAXI [Indiscernible] continue that's to The get build the a great is be lot the on reinspection certainly about and between application I aesthetic over sort its resubmission, clock approval. franchise the that's is FinTech, we're aesthetics, but you unlock one side aesthetic on focus offering X we important and linkage soon as we products and move other therapeutics, FinTech there's set file category. to continue indication competitors We price getting with our that to and ability same and we following and qualification that on dystonia, going an us try it kind are our and be is it we for own that franchise. that, out services value XX:XX in we part out? to, to does laid believe at supplemental a So of given platform, so that of can a in continue don't will of the mean, much the once a of once for new the of so to PDUFA terms that way cervical to BLA that is of we'll – prepared when happens Shifting on for market. we've cell our the given think after sort in will XX:XX challenge know, believe

recognition Of how going positioned we thoughtful value to course, the we right Today, of an to never has always the be where we're like in asset have I that long acting having in be is term. proposition been long important the about long better think the going neuromodulator, we volume think a opportunity shareholder to and and neuromodulator the build community really for we're acting that competitive longer-term. terms

we've it now So, continue focused but sense right kind the we're plan that makes laid know you to of what to very evaluate on out. as most think we we'll the

Annabel Samimy

Okay. Thank Great. XX:XX you.

Operator

XX:XX line of Our with next Barclays. the question Balaji Prasad comes from

You may begin.

Balaji Prasad

couple questions me. Good Thanks XX:XX for questions. from the A evening. of

BLA. on R&D what in would we manufacturing of in filing to doesn't Firstly, to more couple BLA a months case but there, inventory longer file being year? kind X months Two on kind X happen approach? it what or reach help it? the will question, the case to of guided timelines further the question inventory supplemental Assuming non-GAAP was than linked the the inventory? DAXI’s gets for delayed? around this this would There Can costs Thanks. to also happens, happens you Hopefully the And of the is what them towards that need you stand you what one. expensed, or of

Mark Foley

after Mark, dystonia is teed and it This for approval take after for and injection I'll would up for glabellar Yes. to too X. The be for filing for and submit the indication. we already try hand up filed then Phase lines, is we not get and X of sBLA to expect X the X given long to glabellar cervical XX:XX program, approval that wrapped Toby maybe we've that DaxibotulinumtoxinA over X lines

we that we've that given manufactured the So we dating X-year the time thus we've that had on we've reasonable a prepare the accomplish product something we've in think to XX:XX of on And that timeframe, far, is that that application. the inventory manufactured. that can got then a sort

good feel got that to position timing, it. we be leverage we've Obviously, depends inventory. use to able a continue So, and with of a amount in but debating good to like on on we're inventory

So good we position there. in are we number for X? feel a Toby

Toby Schilke

Perfect. product drug substance And inventory, and to each the – both Mark’s and have comments XX:XX Yes. on on expand we Mark’s sequential inventory, drug them. just they on have dating

So that extends further that.

bit and expenses $XX the million XXXX, costs. on the If year at was of were – to look our of XX% of down in was if into non-GAAP just XXK we and the are balance that executing expensed estimate R&D approximately clinical filed were you costs be a as to a break to be expenses not will there that The form R&D further OPUL and to we continue that schedule will you to we're manufacturing between look expenditures costs be, the trials XXXX clinical to expenditures. looking offset DAXI manufacturing by flat the The will and clinical development decline development OPUL continue in we costs the period whereas according for GAAP. back year-on-year

Balaji Prasad

you, XX:XX all. Thank

Mark Foley

XX:XX Thanks, Balaji.

Operator

from Tim Blair. question from next comes Lugo XX:XX William Our

may You begin.

Tim Lugo

the X force XX:XX sales well. like sounds over I talk following has at and you CRLA? all know on how Thanks RHA meeting. shifted has congrats past done for a productive quarters the the Can what the A Type question

I late However, launch? assumed there may have attrition some given the been

Dustin Sjuts

relates break sales a the any kind force see turnover after of is Actually is good Dustin. place. did this really XX:XX not kind Tim, trend to our of We CRL. in as

the have value think that to they upon sell see ready and of OPUL, excited and of how the that the approval. of and RHA, course see organization, advance the portfolio by the into willing and we but or value are the strategies value a I of market strategy aesthetic is see we're to waiting back confident anchored come those aesthetics Revance DAXI, they feel the approaching

So we turn. did significant of see a kind not

at tech the approval. year the in sell that of center and some We headquarters turnover. they kind of significant upon course – have sales centers excited to our see global high organizations, made We the and all was just you time feel to kind change. a healthy we've toward hosted OPUL the Of the innovate here been others you our DAXI been we've team of didn't ranges training first – prepared and for within and it's team Nashville our extremely typically got are and injection end energized live kind left in of and investment RHA, see

Tim Lugo

Good to I granularity QX very know the hear. strong QX aesthetics little the give industry. visits And us of maybe utilization out been XX:XX coming across and on COVID expectations. a could more have growth

quarters. you kind be You year? these strong of know kind typically of for to turbo boost are this seasonally going Can just, they

Mark Foley

as see mentioned kind XX:XX Hey, Tim. in you'll a mid-teens normally the mean, high of Dustin historically, there is to Mark. decline to remarks, This seasonality I and business the QX of prepared in teens. is QX,

the of in we've the Given growth seen that sort market.

that. benefited I from think that QX

kind trend up. QX, be basis, to basis, we that's on So even likely QX again, you a probably relative off reasonable though expect that QX see. back to going QX a And would on relative and a is be of

that's Daxi So tailwind. with will a obviously, obviously, stages and normal seen launch we've even once there's headwinds and tailwinds, the the in that the that we're earlier approved, of still growth But market. seasonal in is trend, be certainly the

Tim Lugo

right. Thank you. XX:XX All

Operator

line Our Tsao Wainwright. of next XX:XX will from Douglas from question come H.C.

may You begin.

Douglas Tsao

Thanks the Hi, for taking good questions. XX:XX afternoon.

Just one clarification.

is runs? for manufacturing have terms us needed work resubmission? done – characterize to runs of that also So that that to together Or Thank the still been the work that those needs in is completed, putting be the terms you completed part the of you. of analytical in have

Mark Foley

XX:XX Yes, Doug.

So analytical completed work we manufacturing have associated with batches. the those

So activities batches. the to manufacturing completed those we've related

Douglas Tsao

so great. Okay, much. Congratulations. XX:XX Thank you

Operator

line of Our question Serge you may XX:XX from begin. next Belanger Needham, comes

Unidentified Analyst

for Serge. for Robin this Thanks on question. Hi, XX:XX is my taking

see it how OPUL as grow growth the it on of terms in to the Just platform when the driver you XXXX? you market? in Do gets expect platform, for DAXI do a

Dustin Sjuts

we're definitely Yeah, OPUL. platform. OPUL excited the with start about I'll Dustin. is This XX:XX

the these features, a know, in As in what can that you those now we're value new current the expanding Phase platform, this while migrating on new technology customers having testing features those building new out to of also customers. focusing also features a next of platform, our new add We're terms and new with it. year of and foundation over on for HintMD

standalone has demand Of excitement in all has course will kind up value bit on in has see value, do right have has then OPUL, items being marketplace we the can a and combination delinked value. of of all of lot pent RHA value. and of impact standalone X a help but DAXI DAXI of sense the the standalone OPUL is a these have account. the

customer. the excited value to we're continue OPUL the and services So progression of to bringing more and

Unidentified Analyst

XX:XX you. Great. Thank

Operator

not back XX:XX showing Thank for you. And I'm Mark closing call the to would in the I any turn questions like over queue. further to remarks. any

Mark Foley

health event care Cowen for through would in reach to plan like this if today's In free for you'd requests Thank participating weeks, in you thank call. welcome all directly the XX:XX the schedule Jessica participate some to of your to that out With you, us. time. conference. to I to Feel We XX:XX or meetings at like coming operator. we

Operator

XX:XX This participating. call. you Thank for conference today's concludes

may Everyone disconnect. You day. great have now a

Revance Therapeutics (RVNC) 1 Mar 222021 Q4 Earnings call transcript